



Docket No. VPI/96-16 CIP *GP 16* *RECEIVED* *#4* *C. Style* *APR 07 2000*

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deepak Rao
Group : 1611
Applicants : Guy W. Bemis et al.
Serial No. : 09/336,266
Filed : June 18, 1999
Title : INHIBITORS OF P38

New York, New York
March 27, 2000

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information
Disclosure Statement in the above-identified application.
This Statement is submitted:

☐ within three months of the application filing
date;

☒ more than three months from the
application filing date but before the
mailing date of the first Office Action on
the merits.

☐ after the mailing date of a first Office
Action on the merits but before the mailing

RECEIVED


APR 07 2000

TECH CENTER 1600/2900

date of a Final Action or a Notice of Allowance.



If, for any reason, a fee is due, the Commissioner is hereby authorized to charge payment of the additional fee required to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Nandakumar Govindaswamy
(Limited Recognition)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

I Heroby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to: ASSISTANT
COMMISSIONER FOR
PATENTS
WASHINGTON, D.C. 20231 on


Claire J. Saintil

Signature of Person Signing



VPI96-16 CIP 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deepak Rao
Group : 1611
Applicants : Guy W. Bemis et al.
Serial No. : 09/336,266
Filed : June 18, 1999
For : INHIBITORS OF P38

New York, New York
March 27, 2000

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorney, make of record the documents listed below.* A completed Form PTO-1449 listing all of the following documents is enclosed herewith in duplicate.

United States Patents

<u>Inventor</u>	<u>Serial No.</u>	<u>Issue Date</u>
Harold G. Selnick et al.	5,717,100	2/10/98
Jerry L. Adams, et al.	5,716,955	2/10/98
Jerry L. Adams, et al.	5,716,972	2/10/98

* Applicants have previously submitted copies of these documents on December 12, 1998, along with the Information Disclosure Statement filed in the parent United States application 08/862,925, filed June 10, 1997.

Foreign Patent Applications

<u>Applicant</u>	<u>Publication No.</u>	<u>Publication Date</u>
Smithkline Beecham Corp.	WO 98/06715	2/19/98
Pfizer Pharmaceuticals Inc.	WO 98/02430	1/22/98
Pharmacia & Upjohn S.P.A.	WO 97/49689	12/31/97
Merck & Co., Inc.	WO 97/47618	12/18/97
Signal Pharmaceuticals, Inc.	WO 97/44467	11/27/97
Merck & Co., Inc.	WO 97/12876	4/10/97
Celltech Therapeutics, Ltd.	WO 97/19065	5/29/97
Smithkline Beecham Corp.	WO 95/31451	11/23/95
Smithkline Beecham Corp.	WO 95/02591	1/26/95

Articles

Timothy F. Gallagher, et al., "Regulation of Stress-Induced Cytokine Production by Pyridinylimidazoles; Inhibition of CSBP Kinase," Bioorganic & Medicinal Chemistry, 5(1), pp. 49-64, (1997).

Alison M. Badger, et al., "Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function," Journal of Pharmacology and Experimental Therapeutics, 279(3), pp. 1453-1461, (1996).

Timothy F. Gallagher, et al., "2,4,5- Triaryl-imidazole Inhibitors of IL-1 Biosynthesis," Bioorganic & Medicinal Chemistry Letters, 5 (11), pp. 1171-1176, (1995).

This Statement is being submitted after the mailing date of the first substantive Action on the merits but before the mailing of a final Action or a Notice of Allowance. In

accordance with 37 C.F.R. §§ 1.97(c) and 1.17(p), applicants have enclosed herewith the requisite fee. If any additional fees are due, the Commissioner is hereby authorized to charge payment of the fee required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075.


Applicants request that these documents: (1) be fully considered by the Examiner during examination of this application, and (2) be printed on any patent that may issue from this application. Applicants request that the Examiner initial and return the duplicate copy of the PTO-1449 form with the next communication.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Nandakumar Govindaswamy
(Limited Recognition)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000

I Hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to: ASSISTANT
COMMISSIONER FOR
PATENTS
WASHINGTON, D.C. 20231 on


March 23, 2000
Claire J. Saintil


Signature of Person Signing